Juan Bailey
Infectious Disease · New York, NYNPI 1205817624
Payments from drug & device makers
Across 316 payments — averaging $80.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$12K
- Janssen Research & Development, LLC$7K
- Viiv Healthcare Company$4K
- Johnson & Johnson$773
- Janssen Products, LP$623
- Hologic Sales And Service, LLC$237
- plus $521 from 7 others
What the payments were for
- Consulting fees$7,18039%
- Travel & lodging$1,90510%
- Food & beverage$9,22750%
- Education$3102%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 107 | $12,313 |
| Janssen Research & Development, LLC | 2 | $6,750 |
| Viiv Healthcare Company | 147 | $4,155 |
| Johnson & Johnson(2 entities) | 38 | $773 |
| Janssen Products, LP | 6 | $623 |
| Hologic Sales And Service, LLC | 1 | $237 |
| AbbVie | 5 | $226 |
| AstraZeneca | 1 | $122 |
| Janssen Scientific Affairs, LLC | 4 | $56 |
| Theratechnologies Inc. | 1 | $47 |
| Merck | 2 | $34 |
| GSK | 1 | $23 |
| Lilly USA, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,372 in reported general payments places this provider in the 85th percentile of 799 infectious disease providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 123 | $503,006 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 19 | $83,310 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 15 | $71,768 |
| PrezcobixDarunavir/Cobicistat | 26 | $59,868 |
| DovatoDolutegravir Sodium/Lamivudine | 16 | $59,123 |
| TivicayDolutegravir Sodium | 24 | $51,833 |
| DescovyEmtricitabine/Tenofov Alafenam | 23 | $48,467 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $44,715 |
| JanuviaSitagliptin Phosphate | 34 | $36,133 |
| JardianceEmpagliflozin | 19 | $25,231 |
| IsentressRaltegravir Potassium | 13 | $24,214 |
| VascepaIcosapent Ethyl | 52 | $20,571 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 37 | $20,448 |
| TrulicityDulaglutide | 11 | $17,099 |
| OzempicSemaglutide | 18 | $16,678 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $12,313 | $596,188158 claims |
| Viiv Healthcare CompanyTriumeq, Dovato, Tivicay | $4,155 | $182,72455 claims |
| Janssen Products, LPSymtuza | $623 | $83,31019 claims |
| MerckJanuvia, Isentress, Janumet Xr | $34 | $80,79584 claims |
| Johnson & JohnsonPrezcobix | $773 | $59,86826 claims |
| Lilly USA, LLCTrulicity | $12 | $17,09911 claims |
| AbbVieLinzess | $226 | $15,54527 claims |
| GSKIncruse Ellipta, Arexvy, Shingrix | $23 | $8,88534 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 799 infectious disease providers in New York.
Other infectious disease in New York
- Wafaa El SadrNew York$119.1M
- Judith AbergNew York$14.8M
- Magdalena SobieszczykNew York$2.9M
- Kristen MarksNew York$2.8M
- Genovefa PapanicolaouNew York$2.7M
- Thomas WalshNew York$1.4M
- Sean LiuNew York$1.4M
- Martin MarkowitzNew York$1.4M
- Angelica KottkampNew York$1.2M
- Michelle CespedesNew York$819K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.